Turn Therapeutics Inc. (NASDAQ:TTRX) Short Interest Down 51.9% in June

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totaling 30,684 shares, a decline of 51.9% from the May 31st total of 63,729 shares. Based on an average daily volume of 72,651 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Turn Therapeutics presently has a consensus rating of “Hold” and an average target price of $8.00.

Get Turn Therapeutics alerts:

View Our Latest Research Report on TTRX

Institutional Investors Weigh In On Turn Therapeutics

Institutional investors have recently bought and sold shares of the stock. Hodges Capital Management Inc. purchased a new stake in Turn Therapeutics in the 4th quarter valued at $39,000. LPL Financial LLC bought a new stake in shares of Turn Therapeutics in the 4th quarter worth $51,000. Tamar Securities LLC purchased a new stake in shares of Turn Therapeutics in the fourth quarter valued at about $59,000. Composition Wealth LLC bought a new position in shares of Turn Therapeutics during the fourth quarter valued at about $63,000. Finally, Jane Street Group LLC bought a new position in shares of Turn Therapeutics during the fourth quarter valued at about $68,000.

Turn Therapeutics Stock Up 6.2%

Shares of NASDAQ:TTRX traded up $0.42 during midday trading on Tuesday, hitting $7.33. 42,677 shares of the company’s stock were exchanged, compared to its average volume of 36,880. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $26.50. The company has a market cap of $218.51 million and a PE ratio of -38.53. The stock has a 50 day moving average price of $4.94 and a 200-day moving average price of $4.14.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Turn Therapeutics Company Profile

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.

Featured Articles

• Five stocks we like better than Turn Therapeutics
• NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
• Amazon Could Be About to Reap the Rewards of a Software Spending Boom
• Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
• AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?

Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.